Surgery – Magnetic field applied to body for therapy
Reexamination Certificate
2011-05-31
2011-05-31
Lacyk, John P (Department: 3735)
Surgery
Magnetic field applied to body for therapy
Reexamination Certificate
active
07951061
ABSTRACT:
Disclosed are devices for targeted delivery of thermotherapy. These devices are useful in the treatment of diseased tissue in conjunction with magnetic compositions. Further disclosed are methods for treating diseased tissue, which involve the administration of a thermotherapeutic magnetic composition to a patient or a portion of a patient, and the application of an alternating magnetic field to inductively heat the thermotherapeutic magnetic composition. The devices and the methods disclosed herein are useful for the treatment of a variety of indications, such as cancer, diseases of the immune system, pathogen-borne diseases, hormone-related diseases, non-cancerous diseased cells or tissue, and undesirable matter, such as toxins and reaction-by-products associated with organ transplants.
REFERENCES:
patent: 4106488 (1978-08-01), Gordon
patent: 4303636 (1981-12-01), Gordon
patent: 4312364 (1982-01-01), Convert
patent: 4323056 (1982-04-01), Borrelli
patent: 4392040 (1983-07-01), Rand
patent: 4452773 (1984-06-01), Molday
patent: 4454234 (1984-06-01), Czerlinski
patent: 4545368 (1985-10-01), Rand et al.
patent: RE32066 (1986-01-01), Leveen
patent: 4569836 (1986-02-01), Gordon
patent: 4574782 (1986-03-01), Borrelli
patent: 4590922 (1986-05-01), Gordon
patent: 4610241 (1986-09-01), Gordon
patent: 4622952 (1986-11-01), Gordon
patent: 4662359 (1987-05-01), Gordon
patent: 4678667 (1987-07-01), Meares
patent: 4708718 (1987-11-01), Daniels
patent: 4735796 (1988-04-01), Gordon
patent: 4753894 (1988-06-01), Frankel
patent: 4758429 (1988-07-01), Gordon
patent: 4767611 (1988-08-01), Gordon
patent: 4813399 (1989-03-01), Gordon
patent: 4889120 (1989-12-01), Gordon
patent: 4923437 (1990-05-01), Gordon
patent: 4950221 (1990-08-01), Gordon
patent: 4979518 (1990-12-01), Itoh
patent: 4983159 (1991-01-01), Rand
patent: 4996991 (1991-03-01), Gordon
patent: 5043101 (1991-08-01), Gordon
patent: 5067952 (1991-11-01), Gudov et al.
patent: 5087438 (1992-02-01), Gordon
patent: 5099756 (1992-03-01), Franconi
patent: 5128147 (1992-07-01), Leveen
patent: 5169774 (1992-12-01), Frankel
patent: 5203782 (1993-04-01), Gudov
patent: 5300750 (1994-04-01), Carter, Jr. et al.
patent: 5411730 (1995-05-01), Kirpotin
patent: 5429583 (1995-07-01), Paulus
patent: 5441746 (1995-08-01), Chagnon
patent: 5468210 (1995-11-01), Matsui
patent: 5506343 (1996-04-01), Kufe
patent: 5547682 (1996-08-01), Chagnon
patent: 5612019 (1997-03-01), Gordon
patent: 5620480 (1997-04-01), Rudie
patent: 5622686 (1997-04-01), Gordon
patent: 5629197 (1997-05-01), Ring
patent: 5658234 (1997-08-01), Dunlavy
patent: 5677171 (1997-10-01), Hudziak
patent: 5693763 (1997-12-01), Codington
patent: 5705157 (1998-01-01), Greene
patent: 5720954 (1998-02-01), Hudziak
patent: 5772997 (1998-06-01), Hudziak
patent: 5859206 (1999-01-01), Vandlen
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio
patent: 5916539 (1999-06-01), Pilgrimm
patent: 5922845 (1999-07-01), Deo
patent: 5935866 (1999-08-01), Chagnon
patent: 5958374 (1999-09-01), Meares
patent: 5968511 (1999-10-01), Akita
patent: 6008203 (1999-12-01), Magnani
patent: 6015567 (2000-01-01), Hudziak
patent: 6037129 (2000-03-01), Cole
patent: 6054561 (2000-04-01), Ring
patent: 6074337 (2000-06-01), Tucker
patent: 6149576 (2000-11-01), Gray
patent: 6165440 (2000-12-01), Esenaliev
patent: 6165464 (2000-12-01), Hudziak
patent: 6167313 (2000-12-01), Gray
patent: 6190870 (2001-02-01), Schmitz
patent: 6242196 (2001-06-01), Spiegelman
patent: 6252050 (2001-06-01), Ashkenazi
patent: 6281202 (2001-08-01), Magnani
patent: 6303755 (2001-10-01), Deo
patent: 6344203 (2002-02-01), Sandrin
patent: 6347633 (2002-02-01), Groth
patent: 6387371 (2002-05-01), Hudziak
patent: 6387888 (2002-05-01), Mincheff
patent: 6391026 (2002-05-01), Hung
patent: 6470220 (2002-10-01), Kraus, Jr. et al.
patent: 6514481 (2003-02-01), Prasad et al.
patent: 6541039 (2003-04-01), Lesniak et al.
patent: 6565887 (2003-05-01), Gray et al.
patent: 6575893 (2003-06-01), Feucht
patent: 6599234 (2003-07-01), Gray et al.
patent: 6638494 (2003-10-01), Pilgrimm
patent: 6669623 (2003-12-01), Jordan
patent: 2001/0011151 (2001-08-01), Feucht
patent: 2001/0012912 (2001-08-01), Feucht
patent: 2002/0052594 (2002-05-01), Goldenberg
patent: 2002/0125975 (2002-09-01), Feucht
patent: 2003/0028071 (2003-02-01), Handy
patent: 2003/0092029 (2003-05-01), Josephson et al.
patent: 2003/0180370 (2003-09-01), Lesniak et al.
patent: 2005/0249817 (2005-11-01), Haik et al.
patent: 2006/0142749 (2006-06-01), Ivkov
patent: 2006/0147380 (2006-07-01), Lanza et al.
patent: 10156790 (2003-06-01), None
patent: 0040512 (1981-11-01), None
patent: 0913167 (1999-05-01), None
patent: 0673255 (2001-08-01), None
patent: 00344270 (2004-11-01), None
patent: 1244767 (1989-09-01), None
patent: 11197257 (1989-09-01), None
patent: 2004/105722 (2004-04-01), None
patent: WO 9411023 (1994-05-01), None
patent: WO 97/43005 (1997-11-01), None
patent: WO 99/19000 (1999-04-01), None
patent: WO 00/52714 (2000-09-01), None
patent: WO 03/047633 (2003-06-01), None
Ivkov et al., Application of High Amplitude Alternating Magnetic Fields for Heat Induction of Nanoparticles Localized in Cancer, 2005, Clin. Can. Res. 11(19Suppl):7093s-7103s.
Denardo et al., Development of Tumor Targeting Bioprones (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy, 2005, Clin. Can. Res. 11(19Suppl.):7087s-7092s.
Peasley, Destruction of human immunodeficiency-infected cells by ferrofluid particles manipulated by an external magnetic field: mechanical disruption and selective introduction of cytotoxic or antiretroviral substances into target cells, 1996, Medical Hypotheses, 46: 5-12, No. 1 England (Abstract).
Torchilin et al., Magnetic sephadex as a carrier for enzyme immobilization and drug targeting, 1985, J of Biomedical Materials Res. 19: 461-466, No. 4 United States (Abstract).
Molina et al., Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, 2001, Cancer Research Jun. 15, 61(12) 4744-4749 (Abstract).
Wong et al., Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells, 2001, Cancer Immunol. Immunother, Apr.; 50(2): 93-101 (Abstract).
Winthrop et al., Development of a hyperimmune anti-MUC-1 single chain antibody fragment phage display library for targeting breast cancer, 1999, Clin Can Research Oct; 5(10 suppl.): 3088-3094.
Richman et al., Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies, 2001, Crit Rev Oncol Hematol 38: 25-35, Ireland (Abstract).
Kobayashi et al., Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes, 2001, Japanese J. of Cancer Res. 92: No. 10 (Abstract).
Young et al., A pulsed power supply system for producing high intensity magnetic and electric fields for medical applications, IEEE Conference Record-Abstracts, PPPS-2001 Pulsed Power Plasma Science 2001, 28th IEEE International Conference on Plasma Science and 13th IEEE International Pulsed Power Conference (Cat. No. 0ICH37255) 2001, pp. 322, USA (Abstract).
Peterson et al.., Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin in breast carcinomas, 1997, Cancer Res. 57(6): 1103-1108 (Abstract).
Diaz et al., Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast, 2001, Breast J. 7(1): 40-45 (Abstract).
Barratt-Boyles, Making the most of mucin: a novel target for tumor immunotherapy, 1996, Cancer Immunol. Immunother. 43(3): 142-151.
Menard et al., Role of Her2 gene overexpression in breast carcinoma, 2000, J. Cell Physiol. 182(2): 150-162 (Abstract).
Hadden, The immunology and immunotherapy of breast cancer: an update, 1999, Int. J. Immunopharacol., 21(2): 79-101 (Abstract).
Tucker et al., Defining the heating characteristics of ferromagnetic implants using calorimetry, 2000, J. of Biomedical Materials Research 53: 791-798 (Abstract).
Takegami et al., New ferromagneti
Daum Wolfgang
Foreman Allan
LandOfFree
Devices for targeted delivery of thermotherapy, and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Devices for targeted delivery of thermotherapy, and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Devices for targeted delivery of thermotherapy, and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698081